Abstract
In order to test the possible effects of lysine vasopressin (LVP) on basal and TRH stimulated TSH and PRL release, an iv bolus of LVP (0.06 lU/kg bw) was injected alone or just before TRH (20 or 400 µg iv) in 18 normal male subjects. The administration of LVP modified neither the basal secretion of TSH and PRL nor the TSH and PRL release induced by 20 or 400 µg TRH. These data suggest that in humans, vasopressin is not involved in the control of TSH and PRL release at the anterior pituitary level.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Heidingsfelder S.A., Blackard W.G. Adrenergic control mechanism for vasopressin-induced plasma growth hormone response. Metabolism 11: 1019, 1968.
Coiro V. Chiodera P., Volpi R., Caiazza A., Salati G., Ferrari P., Pignatti D., Rossi G. Dopaminergic and opioid receptor antagonists do not modify the secretory response of growth hormone to lysine-vasopressin in normal subjects. Neuroendocrinol. Lett. 6: 219, 1984.
Coiro V., Volpi R., Muzzetto P., Caiazza A., Petrolini R., Cerri L., Ruberti G., Chiodera P. Cholinergic muscarinic receptors participate in growth hormone secretion induced by lysine-vasopressin. Horm. Metab. Res. 6: 316, 1985.
Cavagnini F., Raggi U., Micossi P., Landro A., Invitti C. Effect of antiserotoninergic drug, metergoline, on the ACTH and Cortisol response to insulin hypoglycemia and lysine vasopressin in man. J. Clin. Endocrinol. Metab. 43: 306, 1976.
Conte-Devolx B., Oliver C., Foucault-Chiozza F., Giraud P., Castanas E., Codaccioni J.L. Effects de la l-désamino-8-D-arginine-vasopressine sur la fonction corticotrope de l’homme. Nouv. Presse Med. 11: 2566, 1982.
Gillies G., Linton E.A., Lowry P.J. Corticotropin-releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299: 355, 1982.
Chiodera P., Volpi R., Cigarini C., Caiazza A., Marchesi A., Rossi G., Camellini L., Guerra M., Coiro V. Lysine-vasopressin does not affect basal and LH-RH-stimulated LH and FSH release during the menstrual cycle in normal women. Gynecol. Obstet. Invest. 24: 56, 1987.
del Pozo E., Kleinstein J., Brun del Re R., Derrer F., Martin-Perez J. Failure of oxytocin and lysine-vasopressin to stimulate prolactin release in humans. Horm. Metab. Res. 12: 26, 1980.
Swanson L.W., Sawchenko P.E. Paraventricular nucleus: a site for the integrations of neuroendocrine and autonomic mechanisms. Neuroendocrinology 31: 410, 1980.
Koller K.J., Wolff R.S., Warden M.K., Zoeller R.T. Thyroid hormones regulate levels of thyrotropin-releasing-hormone mRNA in the paraventricular nucleus. Proc. Natl. Acad. Sci. USA 84: 7329, 1987.
Segerson T.P., Kauer J., Wolfe H.C., Mobtaker H., Wu P., Jackson I.M.D., Lechan R.M. Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus. Science 238: 78, 1987.
Hartnell J.M., Pekary A.E., Hershman J.M. Comparison of the effects of pulsatile and continuous TRH infusion on TSH release in men. Metabolism 36: 878, 1987.
Snyder P.J., Utiger R.D. Responses to thyrotropin releasing hormone (TRH) in normal man. J. Clin. Endocrinol. Metab. 35: 380, 1972.
Morley J.E. Neuroendocrine control of thyrotropin secretion. Endocr. Rev. 2: 396, 1981.
Yoshida T., Arai T., Sugano J., Yarita H., Yanagisawa H. Isolated ACTH deficiency accompanied by “primary hypothyroidism” and hyperprolactinemia. Acta Endocrinol. (Kbh.) 104: 397, 1983.
Odell W.D., Rayford P.L., Ross G.T. Simplified, partially automated method for radioimmunoassay of human thyroid-stimulating, growth, luteinizing and follicle-stimulating hormones. J. Lab. Clin. Med. 70: 973, 1967.
Sinha Y.N., Selby F.W., Lewis U.J., van der Laan W.P. A homologous radioimmunoassay for human prolactin. J. Clin. Endocrinol. Metab. 36: 509, 1973.
Shin S.H. Vasopressin has a direct effect on prolactin release in male rats. Neuroendocrinology 34: 55, 1982.
Blask D.E., Vaughan M.K., Champney J.H., Johnson R.J., Vaughan G.M., Becker R.A., Reiter R.J. Opioid and dopamine involvement in prolactin release induced by arginine vasotocin and vasopressin in the male rat. Neuroendocrinology 38: 56, 1981.
Lumpkin M.D., Samson W.K., Mc Cann S.M. Arginine vasopressin as a thyrotropin-releasing hormone. Science 235: 1070, 1987.
Zimmerman E.A., Carmel P., Husain M.K., Ferin M., Tannenbaum M., Frantz A.G., Robinson A.G. Vasopressin and neurophysin: high concentrations in monkey hypophyseal portal blood. Science 182: 925, 1973.
Ang V.T.Y., Jenkins J.S. Blood-cerebrospinal fluid barrier to arginine-vasopressin-desmopressin and desglycinamide arginine-vaso-pressin in the dog. J. Endocrinol. 93: 319, 1982.
Sorensen P.S., Vilhardt H., Gjerris F., Warberg J. Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. Eur. J. Clin. Invest. 14: 435, 1984.
Visser T.J. Regulation of the release of TSH. Front. Horm. Res. 14: 100, 1985.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chiodera, P., Gnudi, A., Marchesi, C. et al. Effect of lysine vasopressin on basal and TRH stimulated TSH and PRL release in normal men. J Endocrinol Invest 11, 497–500 (1988). https://doi.org/10.1007/BF03350168
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350168